One of the fundamental limitations of standard peptide protocols is that they are built around population averages. The dosing, the specific peptide selection, the expected timeline for response — all of it is calibrated for a hypothetical average patient. Your actual patient is not average.
ProxiGene™ is a genetic testing service that provides physician-interpretable reports informing how a specific patient is likely to metabolize, respond to, and tolerate peptide and hormone protocols. The question clinical partners ask most often is straightforward: does this actually change outcomes? Here's what early data suggests.
What ProxiGene™ Tests For
ProxiGene™ panels cover several genetic domains relevant to peptide and hormone protocol design:
Metabolic Enzyme Variants
Variants in CYP450 enzyme genes (CYP1A2, CYP2C19, CYP3A4/5) influence how patients metabolize peptides and hormones. A patient who is a poor metabolizer of CYP2C19-pathway compounds will have meaningfully different blood levels from the same dose than an extensive metabolizer. This is clinically significant for dosing decisions.
Hormone Receptor Sensitivity
Variants in androgen receptor genes, estrogen receptor genes, and growth hormone receptor genes influence how robustly a patient responds to hormone modulation. A patient with reduced receptor sensitivity may require a different protocol structure — or may not be an appropriate candidate for certain approaches — compared to a patient with high receptor sensitivity.
Inflammation and Recovery Markers
Variants in IL-6, TNF-alpha, and other inflammatory pathway genes inform baseline inflammatory burden and recovery capacity. This is particularly relevant for patients pursuing tissue support or body composition protocols, where recovery quality directly influences outcomes.
Methylation and Nutrient Processing
MTHFR variants and related methylation pathway genes affect how patients process B vitamins, homocysteine, and related compounds. This informs adjunctive supplementation recommendations that support the primary protocol.
What Standard Protocols Miss
A standard semaglutide weight loss protocol, for example, is designed around typical GLP-1 receptor sensitivity, typical gastric emptying responses, and typical lean mass preservation challenges. It does not account for whether a specific patient has variants associated with lower GLP-1 receptor expression, faster peptide clearance, or impaired muscle protein synthesis.
The clinical result of this mismatch is visible in practice: two patients on identical semaglutide protocols — same starting weight, same age, same activity level — can have dramatically different outcomes. One loses 18% body weight in 6 months. The other loses 6% and experiences significant GI side effects. The physician adjusts by trial and error.
ProxiGene™ reduces the trial-and-error component by providing a genetic map of the factors most likely to drive that variance before the protocol starts.
Early Outcome Data from Partner Clinics
Clinics using ProxiGene-guided protocols are reporting higher 6-month retention rates and lower early discontinuation due to side effects, compared to historical benchmarks on standard protocols.
Three patterns are emerging consistently across clinics running ProxiGene-informed protocols:
Fewer Early Discontinuations
Side-effect-driven early discontinuation — particularly GI effects on GLP-1 protocols and androgenic effects on hormone protocols — drops when initial dosing is calibrated to metabolic enzyme status rather than standard starting doses. Patients with poor metabolizer status who would have received a standard starting dose are started lower and titrated more slowly.
Faster Time to Response in Responder Population
Patients identified as likely robust responders based on receptor sensitivity variants are started more aggressively and reach therapeutic effect faster. This improves the patient experience in the early protocol window — the period when most at-risk patients consider discontinuing.
Better Protocol Matching
Some patients test as poor candidates for specific peptide categories based on their genetic profile. Identifying these patients before protocol initiation — and redirecting them to a better-matched approach — improves overall clinic outcomes data and avoids months of ineffective treatment.
How It Works in Practice
ProxiGene™ is a buccal swab test. The collection kit is mailed to the patient or provided at the clinic. Results are returned to the ordering physician within 7–10 business days as a structured, physician-facing report with protocol recommendations.
The physician reviews the report as part of the initial protocol design consultation. The ProxiGene™ report does not replace clinical judgment — it informs it. The physician still makes all protocol decisions; the genetic data provides a more complete picture than intake forms and bloodwork alone.
Is Genetic Testing Right for Every Patient?
ProxiGene™ adds the most value for patients entering higher-cost or longer-duration protocols: GLP-1 weight loss programs, growth hormone secretagogue protocols, and hormone optimization programs. For a patient considering a 12-month protocol at $500/month, investing in a one-time genetic test that improves the probability of a good outcome is a straightforward value proposition for both the patient and the clinic.
For shorter-duration or lower-cost interventions, the clinical calculus may be different. Medical directors should develop their own criteria for which patient populations benefit most from genetic screening in their specific practice context.
Golden Lotus Labs partners with practices to offer ProxiGene™ testing as part of a complete protocol design service. Partner clinics receive training on report interpretation and integration into clinical workflow.